Tags

Type your tag names separated by a space and hit enter

Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]).
Am J Cardiol. 2013 Jul 01; 112(1):51-6.AJ

Abstract

Randomized trials have established the efficacy of antianginal medications in the treatment of chronic stable coronary disease. Using data from the Global Registry of Acute Coronary Events (GRACE) and Canadian Registry of Acute Coronary Events (CANRACE), we examined the temporal trends in antianginal use (beta blockers, calcium antagonists, and nitrates) before non-ST-elevation acute coronary syndrome presentation from 1999 to 2008 in 10,019 patients. The relationships among previous antianginal use, clinical characteristics on presentation, and in-hospital management and outcomes were examined. Beta blockers were the most commonly used agents, and there was a significant decline in the use of nitrates over time. Compared with patients not on any antianginal therapy before presentation, those on treatment were more likely to be older, female, and have a history of hypertension, diabetes, previous angina, and myocardial infarction; they were less likely to present with positive biomarkers (all p <0.001). Patients not on antianginal therapy before presentation were more likely to undergo coronary angiography and percutaneous coronary intervention and less likely to have recurrent ischemia during hospitalization (all p <0.001). In multivariable analysis, previous antianginal use was independently associated with lower use of coronary angiography in hospital (p = 0.034) but not with in-hospital mortality. In conclusion, there has significant temporal decline in nitrate use before non-ST-elevation acute coronary syndrome. Patients receiving antianginal therapy before presentation more frequently had preexisting cardiovascular disease and previous revascularization and were less likely to present with non-ST-segment elevation MI compared with patients on no antianginal therapies. Previous antianginal use was independently associated with a lower use of coronary angiography in hospital.

Authors+Show Affiliations

Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23582629

Citation

Kang, Jaskaran S., et al. "Management and Outcomes of non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE])." The American Journal of Cardiology, vol. 112, no. 1, 2013, pp. 51-6.
Kang JS, Goodman SG, Yan RT, et al. Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol. 2013;112(1):51-6.
Kang, J. S., Goodman, S. G., Yan, R. T., Lopez-Sendon, J., Pesant, Y., Graham, J. J., Fitchett, D., Wong, G. C., Rose, B. F., Spencer, F. A., & Yan, A. T. (2013). Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). The American Journal of Cardiology, 112(1), 51-6. https://doi.org/10.1016/j.amjcard.2013.02.053
Kang JS, et al. Management and Outcomes of non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). Am J Cardiol. 2013 Jul 1;112(1):51-6. PubMed PMID: 23582629.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management and outcomes of non-ST elevation acute coronary syndromes in relation to previous use of antianginal therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]). AU - Kang,Jaskaran S, AU - Goodman,Shaun G, AU - Yan,Raymond T, AU - Lopez-Sendon,Jose, AU - Pesant,Yves, AU - Graham,John J, AU - Fitchett,David, AU - Wong,Graham C, AU - Rose,Barry F, AU - Spencer,Frederick A, AU - Yan,Andrew T, AU - ,, Y1 - 2013/04/11/ PY - 2012/12/14/received PY - 2013/02/19/revised PY - 2013/02/19/accepted PY - 2013/4/16/entrez PY - 2013/4/16/pubmed PY - 2013/8/21/medline SP - 51 EP - 6 JF - The American journal of cardiology JO - Am J Cardiol VL - 112 IS - 1 N2 - Randomized trials have established the efficacy of antianginal medications in the treatment of chronic stable coronary disease. Using data from the Global Registry of Acute Coronary Events (GRACE) and Canadian Registry of Acute Coronary Events (CANRACE), we examined the temporal trends in antianginal use (beta blockers, calcium antagonists, and nitrates) before non-ST-elevation acute coronary syndrome presentation from 1999 to 2008 in 10,019 patients. The relationships among previous antianginal use, clinical characteristics on presentation, and in-hospital management and outcomes were examined. Beta blockers were the most commonly used agents, and there was a significant decline in the use of nitrates over time. Compared with patients not on any antianginal therapy before presentation, those on treatment were more likely to be older, female, and have a history of hypertension, diabetes, previous angina, and myocardial infarction; they were less likely to present with positive biomarkers (all p <0.001). Patients not on antianginal therapy before presentation were more likely to undergo coronary angiography and percutaneous coronary intervention and less likely to have recurrent ischemia during hospitalization (all p <0.001). In multivariable analysis, previous antianginal use was independently associated with lower use of coronary angiography in hospital (p = 0.034) but not with in-hospital mortality. In conclusion, there has significant temporal decline in nitrate use before non-ST-elevation acute coronary syndrome. Patients receiving antianginal therapy before presentation more frequently had preexisting cardiovascular disease and previous revascularization and were less likely to present with non-ST-segment elevation MI compared with patients on no antianginal therapies. Previous antianginal use was independently associated with a lower use of coronary angiography in hospital. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/23582629/Management_and_outcomes_of_non_ST_elevation_acute_coronary_syndromes_in_relation_to_previous_use_of_antianginal_therapies__from_the_Canadian_Global_Registry_of_Acute_Coronary_Events_[GRACE]_and_Canadian_Registry_of_Acute_Coronary_Events_[CANRACE]__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(13)00708-X DB - PRIME DP - Unbound Medicine ER -